The Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as a multisystem disease closely linked to cardiovascular disease, which is the leading cause of death in this population. MASLD and cardiovascular disease share overlapping pathophysiological mechanisms including insulin resistance, chronic inflammation, oxidative stress, and endothelial dysfunction that not only drive the progression of each disease but may also potentiate one another. Recent initiatives, such as the cardiovascular-kidney-metabolic health framework and the cardiovascular-renal-hepatic-metabolic model, underscore the importance of integrated, multidisciplinary care for managing multisystemic conditions like MASLD. In this context, cardiologists who frequently encounter MASLD-related comorbidities such as diabetes and obesity are well positioned to lead efforts in early detection, risk stratification, and management. This review offers cardiologists a comprehensive overview of MASLD, including the epidemiology, diagnostic approaches, and therapeutic options of MASLD while highlighting cardiologists' pivotal role in its multidisciplinary management.

• Publication year

  2025

• Venue

  Journal of the American College of Cardiology

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2025.08.100PMID 41224405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults: Insights From NHANES 2017 to 2023.

  2025cited by this paper
• Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach

  2025cited by this paper
• Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

  2025cited by this paper
• Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data.

  2025cited by this paper
• Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden.

  2025cited by this paper
• Integrating the care of Metabolic Dysfunction-associated Steatotic Liver Disease into Cardiac Rehabilitation: A Multisystem Approach.

  2025cited by this paper
• Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects.

  2025cited by this paper
• From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework

  2025cited by this paper
• Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease

  2024cited by this paper
• Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria

  2024cited by this paper
• Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study

  2024cited by this paper
• Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

  2024cited by this paper
• Natural history and progression of metabolic dysfunction-associated steatotic liver disease.

  2024cited by this paper
• Integrating liver endpoints in clinical trials of cardiovascular and kidney disease

  2024cited by this paper
• Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease.

  2024cited by this paper
• Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD

  2024cited by this paper
• Observational and genetic association of non-alcoholic fatty liver disease and calcific aortic valve disease

  2024cited by this paper
• Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.

  2024cited by this paper
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

  2024cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2024cited by this paper
• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

  2024cited by this paper
• Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis

  2024cited by this paper
• Metabolic dysfunction-associated steatotic liver disease and atherosclerosis

  2024cited by this paper
• The first MASH drug therapy on the horizon: Current perspectives of resmetirom

  2024cited by this paper
• Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.

  2024cited by this paper
• Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting

  2024cited by this paper
• Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease

  2024cited by this paper
• Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease.

  2024cited by this paper
• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

  2024cited by this paper
• The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement

  2024cited by this paper
• Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies

  2024cited by this paper
• Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study

  2023cited by this paper
• Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study

  2023cited by this paper
• The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

  2023cited by this paper
• Association of HSD17B13 and PNPLA3 with liver enzymes and fibrosis in Hispanic/Latino individuals of diverse genetic ancestries.

  2023cited by this paper
• Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics

  2023cited by this paper
• Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association

  2023cited by this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients

  2023cited by this paper
• Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

  2023cited by this paper
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature

  2023cited by this paper
• Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores

  2023cited by this paper
• Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.

  2023cited by this paper
• Insulin resistance and cardiovascular disease

  2023cited by this paper
• Modulation of Endothelial Function by TMAO, a Gut Microbiota-Derived Metabolite

  2023cited by this paper
• What to Know About PREVENT, the AHA's New Cardiovascular Disease Risk Calculator.

  2023cited by this paper
• A Glimpse into Milestones of Insulin Resistance and an Updated Review of Its Management

  2023cited by this paper
• The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases

  2023cited by this paper
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023cited by this paper
• Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.

  2022cited by this paper
• Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease

  2022cited by this paper
• Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis

  2022cited by this paper
• Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies

  2022cited by this paper
• Global incidence and prevalence of nonalcoholic fatty liver disease

  2022cited by this paper
• Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study

  2022cited by this paper
• The Role of Oxidative Stress in Atherosclerosis

  2022cited by this paper
• Impact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System

  2022cited by this paper
• Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank

  2022cited by this paper
• AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.

  2022cited by this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

  2022cited by this paper
• Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018

  2022cited by this paper
• Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease

  2022cited by this paper
• Surveillance for hepatocellular carcinoma: It is time to move forward

  2022cited by this paper
• IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms.

  2022cited by this paper
• Risk of cardiovascular disease and loss in life expectancy in NAFLD

  2022cited by this paper
• PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

  2021cited by this paper
• NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations

  2021cited by this paper
• Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States

  2021cited by this paper
• Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways.

  2021cited by this paper
• Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches

  2021cited by this paper
• Role of Insulin Resistance in MAFLD

  2021cited by this paper
• Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update.

  2021cited by this paper
• Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis

  2021cited by this paper
• NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH

  2021cited by this paper
• Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.

  2021cited by this paper
• Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries

  2021cited by this paper
• Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

  2021cited by this paper
• Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.

  2021cited by this paper
• Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort

  2021cited by this paper
• Endothelial Dysfunction and Coronary Vasoreactivity - A Review of the History, Physiology, Diagnostic Techniques, and Clinical Relevance

  2020cited by this paper
• High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation

  2020cited by this paper
• Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016

  2020cited by this paper
• Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease

  2020cited by this paper
• Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation

  2020cited by this paper
• Anti-Lipolysis Induced by Insulin in Diverse Pathophysiologic Conditions of Adipose Tissue

  2020cited by this paper
• Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases.

  2020cited by this paper
• Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

  2020cited by this paper
• Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research

  2020cited by this paper
• The PNPLA3-I148M variant confers an antiatherogenic lipid profile in insulin-resistant patients.

  2020cited by this paper
• Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review

  2020cited by this paper
• Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage

  2020cited by this paper
• Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea

  2019cited by this paper
• Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.

  2019cited by this paper
• The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.

  2019cited by this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cited by this paper
• Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysis

  2019cited by this paper
• Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects

  2019cited by this paper
• Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.

  2019cited by this paper
• Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.

  2019cited by this paper
• A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health

  2019cited by this paper
• Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

  2019cited by this paper

• Metabolic Dysfunction-Associated Steatotic Liver Disease and CKM Syndrome: The Role of the Liver in Cardiovascular Risk Stratification.

  2026cites this paper
• Assessing the impact of metabolic dysfunction-associated steatotic liver disease on clinical outcomes in patients with acute myocardial infarction: a national inpatient sample analysis (2018-2020).

  2026cites this paper
• Why the Liver Belongs in Cardiovascular-Kidney-Metabolic Risk Models

  2026cites this paper